Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Bevacizumab in Neoadjuvant Rectal Cancer
NCT07134218Phase 3Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab and bevacizumab in rectal cancer (2 arms), sponsored by Changhai Hospital. Primary endpoint: Clinical Complete Response Rate at 2 years. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
serplulimabbevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07134218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134218.